Marcin Adamczak1, Stanisław Surma1. 1. Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia in Katowice, Katowice, Poland.
Abstract
BACKGROUND: Metabolic acidosis in CKD is diagnosed in patients with plasma or venous blood bicarbonate concentration lower than 22 mmol/L. Metabolic acidosis occurs in about 20% of patients with CKD. Metabolic acidosis may lead to dysfunction of many systems and organs as well as CKD progression. Currently, sodium bicarbonate is mainly used for pharmacological treatment of metabolic acidosis in patients with CKD. Veverimer is a new drug dedicated to treatment of metabolic acidosis in patients with CKD. Orally given veverimer binds hydrogen ions in the intestines and subsequently is excreted from the body with feces. Clinical studies have shown that veverimer is effective in increasing serum bicarbonate concentrations in CKD patients with metabolic acidosis. Here, we present review of the epidemiology, pathogenesis, diagnosis, treatment, and prevention of metabolic acidosis in CKD patients. SUMMARY: Metabolic acidosis is common in patients with CKD and contributes to CKD progression and many complications, which worsen the prognosis in these patients. Currently, sodium bicarbonate is mainly used in metabolic acidosis treatment. The role of the new drug veverimer in the metabolic acidosis therapy needs further studies. KEY MESSAGE: The aim of this review article is to summarize the current knowledge concerning the epidemiology, pathogenesis, diagnosis, treatment, and prevention of metabolic acidosis in CKD patients.
BACKGROUND: Metabolic acidosis in CKD is diagnosed in patients with plasma or venous blood bicarbonate concentration lower than 22 mmol/L. Metabolic acidosis occurs in about 20% of patients with CKD. Metabolic acidosis may lead to dysfunction of many systems and organs as well as CKD progression. Currently, sodium bicarbonate is mainly used for pharmacological treatment of metabolic acidosis in patients with CKD. Veverimer is a new drug dedicated to treatment of metabolic acidosis in patients with CKD. Orally given veverimer binds hydrogen ions in the intestines and subsequently is excreted from the body with feces. Clinical studies have shown that veverimer is effective in increasing serum bicarbonate concentrations in CKD patients with metabolic acidosis. Here, we present review of the epidemiology, pathogenesis, diagnosis, treatment, and prevention of metabolic acidosis in CKD patients. SUMMARY: Metabolic acidosis is common in patients with CKD and contributes to CKD progression and many complications, which worsen the prognosis in these patients. Currently, sodium bicarbonate is mainly used in metabolic acidosis treatment. The role of the new drug veverimer in the metabolic acidosis therapy needs further studies. KEY MESSAGE: The aim of this review article is to summarize the current knowledge concerning the epidemiology, pathogenesis, diagnosis, treatment, and prevention of metabolic acidosis in CKD patients.
Authors: Casey M Rebholz; Josef Coresh; Morgan E Grams; Lyn M Steffen; Cheryl A M Anderson; Lawrence J Appel; Deidra C Crews Journal: Am J Nephrol Date: 2016-01-21 Impact factor: 3.754
Authors: Agata Ziomber; Agnes Machnik; Anke Dahlmann; Peter Dietsch; Franz-Xaver Beck; Hubertus Wagner; Karl F Hilgers; Friedrich C Luft; Kai-Uwe Eckardt; Jens Titze Journal: Am J Physiol Renal Physiol Date: 2008-10-08
Authors: Marcin Adamczak; Anna Masajtis-Zagajewska; Oktawia Mazanowska; Katarzyna Madziarska; Tomasz Stompór; Andrzej Więcek Journal: Kidney Blood Press Res Date: 2018-06-07 Impact factor: 2.687
Authors: Katarzyna Skiba; Damian Gojowy; Magdalena Szotowska; Magdalena Bartmańska; Aureliusz Kolonko; Lech Cierpka; Andrzej Więcek; Marcin Adamczak Journal: Pol Arch Intern Med Date: 2018-09-12